Terazosin: Pharmacokinetics and the effect of age and dose on the incidence of adverse events
- 30 September 1991
- journal article
- research article
- Published by Elsevier in American Heart Journal
- Vol. 122 (3), 901-905
- https://doi.org/10.1016/0002-8703(91)90809-v
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- alpha 1-antagonists in the treatment of hypertension.Hypertension, 1989
- Terazosin: A New Long-Acting α1-Adrenergic Antagonist for HypertensionMedical Clinics of North America, 1988
- Effect of Age on Pharmacokinetics of and Blood Pressure Responses to Prazosin and TerazosinJournal of Cardiovascular Pharmacology, 1987
- Terazosin: An effective once-daily monotherapy for the treatment of hypertensionAmerican Journal Of Medicine, 1986
- Pharmacology of terazosinAmerican Journal Of Medicine, 1986
- Influence of renal insufficiency on the pharmacokinetics and pharmacodynamics of terazosinAmerican Journal Of Medicine, 1986
- Overall safety of terazosin as an antihypertensive agentAmerican Journal Of Medicine, 1986
- Efficacy of terazosin as an antihypertensive agentAmerican Journal Of Medicine, 1986
- Pharmacokinetics of terazosinAmerican Journal Of Medicine, 1986
- Clinical Pharmacokinetics of Prazosin - 1985Clinical Pharmacokinetics, 1985